Adjuvant Aromatase Inhibitor Therapy in Early Breast Cancer: What Factors Lead Patients to Discontinue Treatment?

aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.

(2017) Richard G. Gray et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

(2014) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Interruption and Non-Adherence to Long-Term Adjuvant Hormone Therapy Is Associated with Adverse Survival Outcome of Breast Cancer Women - An Asian Population-Based Study

(2014) Kun-Pin Hsieh et al.   PLoS One

Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer

(2012) N. Lynn Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

(2012) Christina Davies et al.   LANCET

Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer

(2011) Larissa Nekhlyudov et al.   BREAST CANCER RESEARCH AND TREATMENT

Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer

(2011) L Huiart et al.   BRITISH JOURNAL OF CANCER

Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer

(2010) Dawn L. Hershman et al.   BREAST CANCER RESEARCH AND TREATMENT

Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis

(2010) Myrthe P. P. van Herk-Sukel et al.   BREAST CANCER RESEARCH AND TREATMENT

Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients

(2010) Dawn L. Hershman et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology Clinical Practice Guideline Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

(2010) Harold J. Burstein et al.   Journal of Oncology Practice

Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study

(2009) Karine Briot et al.   BREAST CANCER RESEARCH AND TREATMENT

Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer

(2008) C McCowan et al.   BRITISH JOURNAL OF CANCER

Predictors of Tamoxifen Discontinuation Among Older Women With Estrogen Receptor–Positive Breast Cancer

(2007) Cynthia Owusu et al.   JOURNAL OF CLINICAL ONCOLOGY